Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

SVS VQI Postmarket Surveillance


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Ongoing
Application Number /
Requirement Number		 P180001 / PAS002
Date Original Protocol Accepted 12/31/2018
Date Current Protocol Accepted 10/31/2019
Study Name SVS VQI Postmarket Surveillance
Device Name Zenith Dissection Endovascular System
Clinical Trial Number(s) NCT01568320 NCT02094300 NCT02464943 
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source External Registry
Comparison Group No Control
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Objectives New enrollment under the SVS VQI Dissection Project, which will be referred to as the Zenith Dissection Endovascular System Post Approval Study. The objective of this study is to obtain long-term follow-up and additional information regarding the treatment of all types of dissections and reasons for repair.
Study Population Patients with acute or chronic dissections.
Sample Size 120 new patients with acute Type B dissections, who are treated using both the Zenith TX2 Dissection Endovascular Graft with Pro-Form and the Zenith Dissection Endovascular Stent, and 60 new patients with chronic Type B dissections, who are treated using the Zenith Dissection Endovasular System, will be included in the Zenith Dissection Endovascular System Post Approval Study.
Key Study Endpoints The endpoints for the Zenith Dissection Endovascular System Post Approval Study are the following:
Primary safety: Freedom from dissection-related mortality (all devices combined endpoint)
Primary effectiveness: device technical success and device procedural success at 30 days (device-specific endpoints)
Secondary endpoints: elements of device technical (during the procedure) and procedural success (30-day) for each project device; additional endovascular and surgical dissection-related interventions (30days, 1 year, yearly through 5-years); dissection treatment success and the individual elements of the composite endpoint dissection treatment success (30 days, 1 year, yearly through 5-years)
Follow-up Visits and Length of Follow-up 30-days, 1-year and yearly through 5 years


SVS VQI Postmarket Surveillance Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
1 year report 12/31/2019 12/18/2019 On Time
2 year report 12/30/2020 12/16/2020 On Time
3 year report 12/30/2021 12/20/2021 On Time
4 year report 12/30/2022 12/16/2022 On Time
5 year report 12/30/2023 12/20/2023 On Time
6 year report 12/30/2024    


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-